Synapse - Issam Hamadeh

Results (10)

Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses

Meeting Abstract

Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
Clinical Lymphoma, Myeloma and Leukemia (2024)

Fulltext@MSK | Save

Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma

Meeting Abstract

Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
Clinical Lymphoma, Myeloma and Leukemia (2024)

Fulltext@MSK | Save

Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

Journal Article

Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M. L.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
Blood Advances (2024)

Fulltext@MSK | Save

CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma

Journal Article

Firestone, R. S.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Qin, W. G.; Patel, D.; Tan, C. R.; more...
Blood Advances (2024)

Fulltext@MSK | Save

Identifying causes of unscheduled healthcare interactions and changes to patient disposition in individuals receiving outpatient commercial bispecific antibody therapy in relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Howard, A. J.; Shekarkhand, T.; Hamadeh, I. S.; Wang, A.; Patel, D.; Tan, C.; Hultcrantz, M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; more...
Blood (2023)

Fulltext@MSK | Save

Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

Meeting Abstract

Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
Blood (2023)

Fulltext@MSK | Save

Evaluating tumor-intrinsic and patient-specific mechanisms of resistance to teclistamab in anti-BCMA exposed and naïve multiple myeloma

Meeting Abstract

Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I. S.; Wang, A.; Zhu, M.; Patel, D.; Tan, C.; Hultcrantz, M.; more...
Blood (2023)

Fulltext@MSK | Save

Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

Meeting Abstract

Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
Clinical Lymphoma, Myeloma and Leukemia (2023)

Fulltext@MSK | Save

Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma